BeOne Medicines
Quick facts
| Founded | 2010 |
|---|
Phase 3 pipeline
- BGB-16673 · Oncology
BGB-16673 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth. - Intravenous Tislelizumab · Oncology
Tislelizumab is a monoclonal antibody that blocks PD-1 on T cells to enhance anti-tumor immune responses. - Subcutaneous Tislelizumab · Oncology
Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
Phase 1 pipeline
- Anticancer Agents
- BG-71332
- BG-75098
- BG-75202
- BG-89894
- BG-A3004
- BG-C0902
- BG-C0979
- BG-C137
- BG-C477
- BG-C9074
- BGB-21447
- BGB-26808
- BGB-43395
- BGB-58067
- BGB-B2033
- BGB-R046
- CDK4 Inhibitor
- Estrogen Receptor Antagonist
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about BeOne Medicines
What is BeOne Medicines's pipeline?
BeOne Medicines has 3 drugs in Phase 3, 0 in Phase 2, 19 in Phase 1. Late-stage candidates include BGB-16673, Intravenous Tislelizumab, Subcutaneous Tislelizumab.
When was BeOne Medicines founded?
BeOne Medicines was founded in 2010.
Related
- Sector hub: All tracked pharma companies